These results indicated that decitabine treatment can directly regulate the antitumor activity of CD8+ T cells, and decitabine-pretreated CD8+ T cells had high cytotoxicity after PD-1 blockade both in vitro — against tumor cells — and in mouse tumor models. The gene discussed is CD8A; the disease is neoplasm.